LAVCLOR TABLET 16
Chloroquine is used for the treatment and prevention of malaria. The medicine works by stopping and fighting the growth of the parasites in the red blood cells of the human body. It is also used for the treatment of amebiasis (an infection of intestines).
Primaquine is an antimalarial drug administered alone or with another medication for treating malaria (a serious infection spread by mosquitoes which might be fatal sometimes) and to prevent the relapse (stopping the disease from coming back) in people one affected with malaria. In case of Vivax malaria the parasites travel from the bloodstream into other cells and tissues of the body and spread the infection. The drugs works by killing the malaria causing organisms present in the body.
The common side effects of consuming Chloroquine are: vomiting, dizziness, muscle weakness, loss of appetite, hair loss, itching, hearing disorder, blurred vision, visual disturbance, headache, bloating, drowsiness, ringing in ear, skin rashes, abnormal heart rate, eye disorder, mood changes, vision problems, trouble reading or seeing objects, hazy vision, hearing loss, muscle weakness, loss of coordination, nausea, upper stomach pain, dark urine, clay-colored stools, jaundice, fever, sore throa...
The most common side effects of this drug are abdominal pain; epigastric pain; gastrointestinal discomfort; heartburn; back, leg, or stomach pains; dark urine; fever; loss of appetite; pale skin; unusual tiredness or weakness; abdominal cramps; shortness of breath; fast heartbeat; yellowing of the skin or eyes; grey-bluish color of lips and/or skin; or nervousness.
Chloroquine toxic doses may prove fatal, even a 1 gm dose can turn lethal for children. The toxic symptoms would show up in minutes, including headache, drowsiness, cardiovascular collapse, visual disturbances, nausea and vomiting, shock and convulsions followed by sudden and early respiratory and cardiac arrest.
Primaquine phosphate administration is contraindicated in patients who are severely ill and suffering from systemic disease prone to granulocytopenia, such as rheumatoid arthritis and lupus erythematosus; and severe glucose-6-phosphate dehydrogenase (G6PD) deficiency.